3 Articles found
VEO Ophthalmics, LLC Articles
-
Aramis Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial Evaluating A197 for the Treatment of Dry Eye Disease
Aramis Biosciences announced that the first patient has been dosed in its phase 2 proof of concept clinical trial evaluating A197, a novel, first-in-class, topical immunomodulatory agent for the treatment of dry eye disease. “This is an ...
-
Results of the United States Food and Drug Administration Clinical Trial of the CustomFlex Artificial Iris
Purpose To evaluate safety and efficacy of a custom-manufactured artificial iris device (CustomFlex Artificial Iris; HumanOptics AG) for the treatment of congenital and acquired iris defects. Design Multicenter, prospective, unmasked, ...
-
FDA clears first artificial iris by HumanOptics
The first stand-alone prosthetic iris has received regulatory approval in the United States. CustomFlex Artificial Iris (HumanOptics) is a flexible silicone device indicated for adults and children with congenital aniridia or iris defects due to ...